Study On The Difference Of Secretory Proteins Between Benign And Malignant Cells Of Prostate

Objective: To differentiate the expression of secretory proteins between benign and malignant cells of prostate, in order to identify novel biomarker and elucidate the mechanism of development and progression of PCa. Methods: Separate secretory proteins by 2D-electrophoresis, followed by the identification of disparate points by MS. Then verify the results in vitro by real time quantitative PCR. Finally, clinical test of CKB was carried out. Results: CD 13 spots were identified successfully by MS. 5 spots were in BPH1 gel (Laminin, gamma 2, 6-phosphoglucono -lactonase+ERP29 isoform 1 precursor, MTAP, GSTPi, Hypothetical protein BC004224). 8 spots were in LNCaP gel(CKB, Cypa Mutant K131a, Cypa Complexed with Hvgpia, RGS10, NADP+-IDH, Aldehyde Reductase, TPI, Glyoxalase I ). ?The results of Real-time PCR showed that CKB expression in LNCaP, C4-2, and C4-2b malignant cells was up-regulated by 12.3, 12.4 and 11.9 times, respectively. However, MTAP was down-regulated by 0.35, 0.35 and 0.09 times, respectively. (3)the difference of CKB positive rate between the patients without hormone therapy and the patients with BPH is significant. Conclusion: The difference of secretory proteins between benign and malignant cells is significant. The disparate proteins may be candidate biomarker or may elucidate the mechanism of development and progression of PCa. The study establishes the foundation for identification of biomarker and elucidation of mechanism of prostate cancer.